AR065338A1 - Metodo para tratar o prevenir deterioro, lesion o dano de tejidos debido a enfermedad de las mucosas - Google Patents

Metodo para tratar o prevenir deterioro, lesion o dano de tejidos debido a enfermedad de las mucosas

Info

Publication number
AR065338A1
AR065338A1 ARP080100621A ARP080100621A AR065338A1 AR 065338 A1 AR065338 A1 AR 065338A1 AR P080100621 A ARP080100621 A AR P080100621A AR P080100621 A ARP080100621 A AR P080100621A AR 065338 A1 AR065338 A1 AR 065338A1
Authority
AR
Argentina
Prior art keywords
disease
injury
damage
mucose
treat
Prior art date
Application number
ARP080100621A
Other languages
English (en)
Spanish (es)
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of AR065338A1 publication Critical patent/AR065338A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP080100621A 2007-02-13 2008-02-13 Metodo para tratar o prevenir deterioro, lesion o dano de tejidos debido a enfermedad de las mucosas AR065338A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90097707P 2007-02-13 2007-02-13

Publications (1)

Publication Number Publication Date
AR065338A1 true AR065338A1 (es) 2009-06-03

Family

ID=39690681

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100621A AR065338A1 (es) 2007-02-13 2008-02-13 Metodo para tratar o prevenir deterioro, lesion o dano de tejidos debido a enfermedad de las mucosas

Country Status (14)

Country Link
US (2) US7906486B2 (cg-RX-API-DMAC7.html)
EP (1) EP2120986A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010518160A (cg-RX-API-DMAC7.html)
KR (1) KR20090119897A (cg-RX-API-DMAC7.html)
CN (1) CN101657210A (cg-RX-API-DMAC7.html)
AR (1) AR065338A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008216799A1 (cg-RX-API-DMAC7.html)
CA (1) CA2677749A1 (cg-RX-API-DMAC7.html)
IL (1) IL200364A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009008641A (cg-RX-API-DMAC7.html)
NZ (1) NZ579570A (cg-RX-API-DMAC7.html)
TW (1) TW200845958A (cg-RX-API-DMAC7.html)
UA (1) UA96980C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008100458A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009008641A (es) * 2007-02-13 2009-09-14 Sciclone Pharmaceuticals Inc Composiciones para el tratamiento o prevencion del deterioro, lesion o daño a tejido debido a enfermedad de las mucosas.
RU2436587C1 (ru) * 2010-10-21 2011-12-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") N-изовалероил-l-глутамил-l-триптофан как средство, препятствующее язвообразованию в желудке и двенадцатиперстной кишке
CN109528202B (zh) * 2018-11-14 2021-07-16 北京大学第一医院 一种头颈部放疗诊疗系统

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125626A (en) 1977-01-17 1978-11-14 Mt. Sinai School Of Medicine Of The City University Of New York Synthesis and use of L-γ-glutamyl-DOPA
US4568489A (en) 1984-06-29 1986-02-04 E. R. Squibb & Sons, Inc. N-Acyl-γ-glutamyl imino and amino acids and esters
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4758551A (en) 1986-07-08 1988-07-19 Cornell Research Foundation, Inc. Methods for combatting renal toxicity due to metals or nephrotoxic drugs and for selectively modulating in vivo formation of leukotriene types
US4968672A (en) 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US4895835A (en) 1987-11-20 1990-01-23 Nisshin Oil Mills, Ltd. Muramyl peptide derivatives and use thereof
US5728680A (en) * 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
US5902790A (en) 1995-10-03 1999-05-11 Cytran, Inc. Pharmaceutical angiostatic dipeptide compositions and method of use thereof
US5206220A (en) 1990-04-23 1993-04-27 Research Corporation Technologies, Inc. Soluble and stable sources of tyrosine, cysteine and glutamine for total parenteral nutrition
WO1992017191A1 (en) 1991-04-01 1992-10-15 Cytoven Pharmaceutical dipeptide compositions and methods of use thereof
DE69230500D1 (de) 1991-10-28 2000-02-03 Cytran Ltd Pharmazeutische Dipeptid Zusammensetzungen und Verwendungsmethoden.
AU6359594A (en) 1993-03-04 1994-09-26 Cytoven International N.V. Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
GB9320820D0 (en) 1993-10-08 1993-12-01 Biokine Tech Ltd Compounds for medicinal use
RU2107692C1 (ru) 1995-06-07 1998-03-27 Дейгин Владислав Исакович Пептид и способ его получения
US5888980A (en) 1994-06-30 1999-03-30 Bio-Logic Research And Development Corporation Compositions for enhancing immune function
WO1997019691A1 (en) 1995-11-28 1997-06-05 Wei, Edward, T. Gamma-l-glutamyl containing immunomodulator compounds and methods therewith
US5744452A (en) 1995-11-28 1998-04-28 Edward T. Wei γ-L-glutamyl containing immunomodulator compounds and methods therewith
RU2120298C1 (ru) 1995-11-28 1998-10-20 Товарищество с ограниченной ответственностью "Верта" Иммуностимулятор и препарат на его основе
US5916878A (en) 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
US6060452A (en) 1996-03-13 2000-05-09 Cytran, Inc. Analogs of L-Glu-L-Trp having pharmacological activity
RU2141483C1 (ru) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
RU2229892C2 (ru) 2001-06-08 2004-06-10 Государственное учреждение "Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии" Способ лечения туберкулеза легких
US7173013B2 (en) 2001-06-08 2007-02-06 Sciclone Pharmaceuticals, Inc. Treatment of tuberculosis using immunomodulator compounds
US20050256042A1 (en) * 2003-05-09 2005-11-17 Jeffers Michael E Methods of preventing and treating alimentary mucositis
MXPA06013050A (es) * 2004-05-14 2007-03-28 Sciclone Pharmaceuticals Inc Composiciones a base de compuestos inmunoreguladores para el tratamiento o prevencion de infecciones virales respiratorias.
AU2005299609A1 (en) 2004-10-27 2006-05-04 Sciclone Pharmaceuticals, Inc. Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds
WO2006076169A2 (en) 2004-12-28 2006-07-20 Sciclone Pharmaceuticals, Inc. Treatment or prevention of genital viral infections with immunomodulator compounds
US20090074815A1 (en) 2005-04-22 2009-03-19 Sciclone Pharmaceuticals, Inc. Immunomodulator Compounds as Vaccine Enhancers
CA2649575A1 (en) 2006-04-20 2007-11-01 Sciclone Pharmaceuticals, Inc. Treatment of melanoma
KR20090094145A (ko) 2006-12-18 2009-09-03 아칠리온 파르마세우티칼스 인코포레이티드 C형 간염 감염을 치료하기 위한 병용 요법
MX2009008641A (es) * 2007-02-13 2009-09-14 Sciclone Pharmaceuticals Inc Composiciones para el tratamiento o prevencion del deterioro, lesion o daño a tejido debido a enfermedad de las mucosas.
RU2007118237A (ru) 2007-05-17 2008-11-27 ООО "Научно-производственна фирма Верта" (RU) Способ лечения аллергических заболеваний
UA98508C2 (ru) 2007-08-23 2012-05-25 Сайклон Фармасьютикалз, Инк. Иммуномодуляторное производное дипептида для лечения рака легких
JP2011530519A (ja) 2008-08-06 2011-12-22 サイクローン・ファーマシューティカルズ・インコーポレイテッド 免疫調節化合物を用いたc型肝炎の治療または予防の方法

Also Published As

Publication number Publication date
IL200364A0 (en) 2010-04-29
AU2008216799A1 (en) 2008-08-21
MX2009008641A (es) 2009-09-14
WO2008100458A3 (en) 2008-11-27
JP2010518160A (ja) 2010-05-27
EP2120986A2 (en) 2009-11-25
US20100086622A1 (en) 2010-04-08
NZ579570A (en) 2012-02-24
WO2008100458A2 (en) 2008-08-21
CN101657210A (zh) 2010-02-24
US7906486B2 (en) 2011-03-15
US20110117211A1 (en) 2011-05-19
UA96980C2 (ru) 2011-12-26
KR20090119897A (ko) 2009-11-20
TW200845958A (en) 2008-12-01
EP2120986A4 (en) 2010-04-07
CA2677749A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
ES2356883A1 (es) Composicion para el tratamiento del dolor y/o la inflamacion.
ECSP066653A (es) Derivados de bencenosulfonilamino-piridin-2-il y compuestos relacionados como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1(ii-beta-hsd-1) para el tratamiento de la diabetes y de la obesidad
AR075204A1 (es) Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
ECSP12011582A (es) Terapia de combinación para el tratamiento de la diabetes
GT201100181A (es) "inhibidores de proteina cinasa"
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
RU2010144637A (ru) Замещенные гамма-лактамы в качестве терапевтических агентов
AR060089A1 (es) Tratamiento del dolor
GT201200038A (es) Composicion para tratar la fibrosis quistica
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
AR047513A1 (es) Metodos y composiciones para el tratamiento de cambios en la piel relacionados con el envejecimiento y los danos ocasionados por el medio ambiente
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
NO20061625L (no) Behandling og/eller forhindring av urininkontinens ved bruk av prolegemidler av gaba analoger
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
ECSP088545A (es) Composición para prevenir o tratar daños de la mucosa en los conductos gastrointestinales
WO2012135597A3 (en) Novel, protective, anti-inflammatory receptor and its use in preservation of mitochondrial function, wound healing and repair
UY30557A1 (es) Tratamiento y prevencion de la fibrosis intestinal
CO2023004447A2 (es) Composiciones y métodos para el tratamiento de distrofias musculares
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
ES2555785T3 (es) Remedio o preventivo para esquizofrenia
WO2007014253A3 (en) Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure
CU20130004A7 (es) Agentes terapéuticos 976

Legal Events

Date Code Title Description
FA Abandonment or withdrawal